Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more
Milestone Pharmaceuticals Inc (MIST) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.479x
Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) has a cash flow conversion efficiency ratio of -0.479x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.82 Million) by net assets ($20.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Milestone Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Milestone Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Milestone Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Milestone Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AGRANA Beteiligungs-Aktiengesellschaft
VI:AGR
|
0.011x |
|
Merchants Financial Group Inc
PINK:MFGI
|
0.021x |
|
CompuGroup Medical AG O.N.
LSE:0MSD
|
0.144x |
|
Global Indemnity PLC
NYSE:GBLI
|
0.010x |
|
Ningbo Tianyi Medical Appliance Co. Ltd.
SHE:301097
|
N/A |
|
Amcil Ltd
AU:AMH
|
0.012x |
|
APT Satellite Holdings Limited
STU:AY8
|
0.017x |
|
Everspin Technologies Inc
NASDAQ:MRAM
|
0.013x |
Annual Cash Flow Conversion Efficiency for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Milestone Pharmaceuticals Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.15 Million | $-28.85 Million | -2.194x | +20.73% |
| 2023-12-31 | $16.77 Million | $-46.42 Million | -2.768x | -250.03% |
| 2022-12-31 | $66.35 Million | $-52.47 Million | -0.791x | -168.02% |
| 2021-12-31 | $112.60 Million | $-33.22 Million | -0.295x | +16.76% |
| 2020-12-31 | $143.12 Million | $-50.73 Million | -0.354x | +20.36% |
| 2019-12-31 | $114.92 Million | $-51.15 Million | -0.445x | -216.77% |
| 2018-12-31 | $-55.21 Million | $-21.05 Million | 0.381x | +56.79% |
| 2017-12-31 | $-33.12 Million | $-8.05 Million | 0.243x | -- |